MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-20-2026
AbbVie Accounts Payables 2011-2026 | ABBV
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables AbbVie
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.59 B | 2.94 B | 3.69 B | 2.93 B | 2.88 B | 2.28 B | 1.45 B | 1.55 B | 1.47 B | 1.41 B | 1.6 B | 881 M | 933 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.69 B | 881 M | 2.12 B |
Quarterly Accounts Payables AbbVie
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | 2.88 B | - | - | - | 2.28 B | - | - | - | 1.45 B | - | - | - | 1.55 B | - | - | - | 1.47 B | - | - | - | 1.41 B | - | - | - | 1.6 B | - | - | - | 1.4 B | - | - | - | 933 M | - | - | - | 556 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.88 B | 556 M | 1.55 B |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Amgen
AMGN
|
2.37 B | $ 350.62 | 0.81 % | $ 189 B |  USA |
 |
Heron Therapeutics
HRTX
|
8.99 M | $ 0.8 | 2.35 % | $ 133 M | USA |
 |
Altimmune
ALT
|
2.72 M | $ 3.46 | 3.44 % | $ 305 M | USA |
 |
I-Mab
IMAB
|
570 M | - | - | $ 866 M |  China |
 |
Applied Genetic Technologies Corporation
AGTC
|
2.91 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
3.46 M | - | 1052.0 % | $ 415 M | USA |
 |
Incyte Corporation
INCY
|
210 M | $ 90.74 | -0.04 % | $ 17.7 B | USA |
 |
AgeX Therapeutics
AGE
|
1.41 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | USA |
 |
Inovio Pharmaceuticals
INO
|
23.3 M | $ 1.62 | 2.22 % | $ 35.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
911 K | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
601 K | - | 4.01 % | $ 150 M |  Canada |
 |
Avenue Therapeutics
ATXI
|
155 K | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
1.61 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
3.81 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
6.08 M | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
841 K | $ 12.92 | 1.41 % | $ 778 M | USA |
 |
Atreca
BCEL
|
1.74 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
8.11 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
479 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
KalVista Pharmaceuticals
KALV
|
4.88 M | $ 16.76 | -1.41 % | $ 832 M |  Britain |
 |
Calithera Biosciences
CALA
|
3.65 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
11.6 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
6.75 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
1.23 M | - | -74.18 % | $ 955 K | USA |
 |
Checkpoint Therapeutics
CKPT
|
6.09 M | - | - | $ 169 M | USA |
 |
Karyopharm Therapeutics
KPTI
|
5.11 M | $ 7.06 | -7.47 % | $ 860 K | USA |
 |
Clovis Oncology
CLVS
|
27.3 M | - | -7.23 % | $ 13 M | USA |
 |
Keros Therapeutics
KROS
|
1.97 M | $ 11.27 | 2.83 % | $ 419 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | USA |
 |
Denali Therapeutics
DNLI
|
11.1 M | $ 21.23 | 5.26 % | $ 3.49 B | USA |
 |
Longeveron
LGVN
|
423 K | $ 0.95 | -3.52 % | $ 16.7 B | USA |
 |
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
3.22 M | $ 4.3 | 1.3 % | $ 714 M | Canada |
 |
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | USA |